Astraea
AI Operating System for Clinical Development
About Astraea
Astraea automates clinical trial biometrics from raw study inputs to FDA-ready outputs. The platform handles data normalization, CDISC mapping, SDTM, ADaM, TFLs, QC, and revision workflows in one auditable system, helping Phase II/III sponsors reduce months of manual programming and data management into automated, reviewable execution.
Public traction evidence
Each signal links to the public source used for attribution.
- X
I’ve burned through 30.2B GPT-5.5 tokens in the last 2 months on Astraea. At public pricing, that’s roughly $30k-$225k+ of equivalent API usage depending on cache/output mix. My cost: 800 bucks. Lesson learned: Token maxxing > token saving. Cheap runs that fail aren’t Show more
I’ve burned through 30.2B GPT-5.5 tokens in the last 2 months on Astraea. At public pricing, that’s roughly $30k-$225k+ of equivalent API usage depending on cache/output mix. My cost: 800 bucks. Lesson learned: Token maxxing > token saving. Cheap runs that fail aren’t Show more
- X
Astraea just launched on @ycombinator's Launch YC!
Astraea just launched on @ycombinator's Launch YC!
- X
Your biostatistics team didn't sign up to spend 60% of their time wrangling SDTM mapping errors.
Your biostatistics team didn't sign up to spend 60% of their time wrangling SDTM mapping errors. They signed up to analyze data. We built Astraea to give them that time back.
- X
Replacing legacy pharma pipeline inefficiency
Most pharma companies spend 6-8 months on SDTM and ADaM. That's not rigor. That's legacy pipeline inefficiency. The data hasn't changed. Only the tools have.